Henagliflozin study in obese patients targets myocardial fibrosis with MRI-based measure — LiveFuture News
Open on LiveFuture.ai →

Henagliflozin study in obese patients targets myocardial fibrosis with MRI-based measure

A new not-yet-recruiting registry study will test Henagliflozin 10 mg against Metformin in obese patients, using cardiac MRI to track myocardial extracellular volume fraction over 24 weeks.

A new registry study is set to test Henagliflozin 10 mg against Metformin in obese patients, with the heart as the focus. The study is listed as NOT_YET_RECRUITING and has no results posted, so it is still in the planning stage rather than a settled finding.

For a general reader, the key point is simple: the trial is looking at myocardial fibrosis, which means scarring in heart tissue. Its primary measure is the change from baseline in myocardial extracellular volume, or ECV, fraction at 24 weeks, a scan-based way to track how much fibrous tissue is present.

This record describes a study and its registry status; study outcomes require posted results.

How the study is designed

The study title is Henagliflozin on Myocardial Fibrosis in Obese Patients. It uses a RANDOMIZED design with two arm groups: an Intervention Group and a Control Group.

The Intervention Group receives Henagliflozin 10 mg, while the Control Group receives Metformin. That setup gives the study a direct comparison between two named drug approaches instead of a single-arm observation.

The between-group difference in ΔECV (Henagliflozin vs. Metformin) will be compared; continuous data will be summarized as mean ± SD and analyzed using mixed-effects models.

Why the outcome matters

The outcome is tied to cardiac magnetic resonance, or CMR, T1 mapping before and after contrast. In plain language, the study is trying to see whether the heart tissue measurement changes over time and whether the change differs between the two groups.

The planned primary completion date is 2028-10, which means this is not a quick readout. For readers following obesity research, it adds to a broader stream of studies in the same topic area, including trials on exercise, diet, and other treatments already linked through the Obesity & Metabolic special event.

Change from baseline in myocardial extracellular volume (ECV) fraction, as measured by cardiac magnetic resonance (CMR) T1 mapping pre- and post-contrast.